News
Public · Published
Kodiak Sciences Reports Q3 2026 Net Loss of $66.2 Million, $88.7 Million in Cash
Kodiak Sciences reported a third-quarter 2026 net loss of $66.2 million, or $1.05 per share, compared with a $61.5 million loss a year earlier. Research and development spending rose to $58.3 million, and cash was $88.7 million at quarter-end. After the quarter, it raised $69 million through an at-the-market share offering.
Published:
Updated:
What happened
Kodiak Sciences reported a third-quarter 2026 net loss of $66.2 million, or $1.05 per share, compared with a $61.5 million loss a year earlier. Research and development spending rose to $58.3 million, and cash was $88.7 million at quarter-end. After the quarter, it raised $69 million through an at-the-market share offering.
Confirmed
Global impact / market context
The larger quarterly loss and rising research spending show that developing treatments is consuming substantial cash. The $69 million share sale added funds after quarter-end, but issuing shares can dilute existing ownership; investors will weigh that funding against the company’s reported cash and future spending needs.
Analyst inference
Kodiak’s report combines financial pressure with a positive study result: Zenkuda met its Phase 3 DAYBREAK primary endpoint, the main measure the trial was designed to test. That result and the planned fourth-quarter 2026 regulatory submission may shape expectations, but neither establishes approval or future sales.
Analyst inference
What to watch
- Watch whether Kodiak submits the planned multi-indication Zenkuda application in the fourth quarter of 2026, as stated, and what the filing says about its scope. Proposed
- Track cash and spending in upcoming reports: research and development costs rose year over year, while the $69 million share sale provided additional funds after quarter-end. Analyst inference
- Follow any further details on DAYBREAK’s results and reported safety, since the company said the trial met its main endpoint and safety matched aflibercept’s established profile. Analyst inference
Evidence
- Original source link unavailable